Nuclear factor-κB expression as a novel marker of radioresistance in early-stage laryngeal cancer

Head and Neck

Volumn 32, Issue 5, 2010, Pages 646-655

  Yoshida, Kenji ^a   Sasaki, Ryohei ^a   Nishimura, Hideki ^a   Okamoto, Yoshiaki ^a   Suzuki, Yoko ^a   Kawabe, Tetsuya ^a   Saito, Miki ^a   Otsuki, Naoki ^a   Hayashi, Yoshitake ^a   Soejima, Toshinori ^b   Nibu, Kenichi ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

Author keywords

Early stage laryngeal cancer; Immunohistochemistry; Nuclear factor B; Radioresistance; Radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; TUMOR MARKER;

ADULT; ARTICLE; BIOPSY; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; CASE CONTROL STUDY; LARYNX TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77951525664     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21239     Document Type: Article

References (41)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Shaha AR, Shah JP. Carcinoma of the subglottic larynx. Am J Surg 1982;144:456-458.
3. Mendenhall WM, Mancuso AA, Hinerman RW, et al. Multidisciplinary management of laryngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:S12-S14.
4. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer 2004;100:1786-1792.
5. Ton-Van J, Lefebvre JL, Stern JC, Buisset E, Coche-Dequeant B, Vankemmel B. Comparison of surgery and radiotherapy in T1 and T2 glottic carcinomas. Am J Surg 1991;162:337-340.
6. Benninger MS, Gillen J, Thieme P, Jacobson B, Dragovich J. Factors associated with recurrence and voice quality following radiation therapy for T1 and T2 glottic carcinomas. Laryngoscope 1994;104:294-298.
7. Krengli M, Policarpo M, Manfredda I, et al. Voice quality after treatment for T1a glottic carcinoma - radiotherapy versus laser cordectomy. Acta Oncol 2004; 43:284-289.
8. McGuirt WF, Blalock D, Koufman JA, et al. Comparative voice results after laser resection or irradiation of T1 vocal cord carcinoma. Arch Otolaryngol Head Neck Surg 1994;120:951-955.
9. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693-3704.
10. McLaughlin MP, Parsons JT, Fein DA, et al. Salvage surgery after radiotherapy failure in T1-T2 squamous cell carcinoma of the glottic larynx. Head Neck 1996; 18:229-235.
11. Burke LS, Greven KM, McGuirt WT, Case D, Hoen HM, Raben M. Definitive radiotherapy for early glottic carcinoma: prognostic factors and implications for treatment. Int J Radiat Oncol Biol Phys 1997;38:1001-1006. (Pubitemid 27353679)
12. Small W Jr, Mittal BB, Brand WN, et al. Results of radiation therapy in early glottic carcinoma: multivariate analysis of prognostic and radiation therapy variables. Radiology 1992;183:789-794.
13. Pai HH, Rochon L, Clark B, Black M, Shenouda G. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41:37-42.
14. Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N. Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 2005;92:2185-2189.
15. Demiral AN, Sarioglu S, Birlik B, Sen M, Kinay M. Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Larynx 2004;31:417-424.
16. Parikh RR, Yang Q, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007;109:566-573.
17. Nix PA, Greenman J, Cawkwell L, Stafford N. Radioresistant laryngeal cancer: beyond the TNM stage. Clin Otolaryngol Allied Sci 2004;29:105-114. (Pubitemid 38534726)
18. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-208.
19. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Ann Rev Immunol 2000;18:621-663.
20. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
21. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
22. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Ann Rev Immunol 1998;16:225-260.
23. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor-κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-754.
24. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-κB. Nat Rev Immunol 2005;6:435-445.
25. Ross JS, Kallakury BV, Sheehan CE, et al. Expression of nuclear factor-κB and IκB alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-κB immunoreactivity with disease recurrence. Clin Cancer Res 2004;10:2466-2472.
26. Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer 2002;100:472-475.
27. Ogawa T, Shiga K, Tateda M, et al. Protein expression of p53 and Bcl-2 has a strong correlation with radiation resistance of laryngeal squamous cell carcinoma but does not predict the radiation failure before treatment. Oncol Rep 2003;10:1461-1466.
28. Kamijo T, Yokose T, Hasebe T, et al. Potential role of microvessel density in predicting radiosensitivity of T1 and T2 stage laryngeal squamous cell carcinoma treated with radiotherapy. Clin Cancer Res 2000;6: 3159-3165.
29. Wen QH, Miwa T, Yoshizaki, T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-888. (Pubitemid 26242129)
30. Sasaki N, Morisaki T, Hashizume K, et al. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136-4142.
31. Le QT, Fu KK, Kroll S, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997;39: 115-126.
32. Rudoltz MS, Benammar A, Mohiuddin M. Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis. Int J Radiat Oncol Biol Phys 1993;26:767-772.
33. Terhaard CH, Snippe K, Ravasz LA, van der Tweel I, Hordijk GJ. Radiotherapy in T1 laryngeal cancer: prognostic factors for locoregional control and survival, uni- and multivariate analysis. Int J Radiat Oncol Biol Phys 1991;21:1179-1186.
34. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor-κB. J Clin Invest 1991;88:691-695.
35. Voboril R, Weberova-Voborilova J. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-κB. Neoplasma 2007;54: 495-502.
36. Fan M, Ahmed KM, Coleman MC, Spitz DR, Li JJ. Nuclear factor-κB and manganese superoxide dismutase mediate adaptive radioresistance in low-dose irradiated mouse skin epithelial cells. Cancer Res 2007;67:3220-3228.
37. Ahmed KM, Li JJ. NF-κB-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008;44:1-13.
38. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-1412.
39. Wang Y, Meng A, Lang H, et al. Activation of nuclear factor κB In vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res 2004;64:6240-6246.
40. Egan LJ, Eckmann L, Greten FR, et al. IκB-kinase beta-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004;101:2452-2457.
41. Sonis ST. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 2002;13:380-389.